Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149271 | 0.75 | BACE1 (0.60) | BACE1KDM4ESMN1; SMN2HTT | |
| SCHEMBL4493177 | 0.71 | BACE1 (0.63) | BACE1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL4149124 | 0.71 | BACE1 (0.76) | BACE1KDM4EPSDCYP3A4HSD17B10 | |
| SCHEMBL28505449 | 0.70 | NCF1 (0.54) | BACE1KDM4ESMN1; SMN2HTTKMT2A | |
| SCHEMBL28849339 | 0.69 | NUDT1 (0.43) | BACE1KMT2A | |
| SCHEMBL27966111 | 0.68 | KMT2A (0.40) | BACE1KMT2A | |
| SCHEMBL4639744 | 0.68 | BACE1 (0.41) | BACE1KDM4EKMT2A | |
| SCHEMBL6403829 | 0.67 | BACE1 (0.49) | BACE1KDM4E | |
| SCHEMBL4148126 | 0.67 | BACE1 (0.57) | BACE1KDM4ESMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL4142484 | 0.67 | BACE1 (1.00) | BACE1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | BACE1 3/4885KDM4E 3305/4885PSD 250/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | BACE1 4/4885KDM4E 3237/4885PSD 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.